Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 4
Submit an article Journal homepage
599
Views
31
CrossRef citations to date
0
Altmetric
Letter

Treatment of chronic myelomonocytic leukemia with azacitidine

Eric WongDepartment of Hematology, Peter MacCallum Cancer Centre, East Melbourne, Australia
,
John F. SeymourDepartment of Hematology, Peter MacCallum Cancer Centre, East Melbourne, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia
,
Melita KenealyCabrini Medical Centre, Malvern, Australia
,
David WestermanDepartment of Hematology, Peter MacCallum Cancer Centre, East Melbourne, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia
,
Kirsten HerbertDepartment of Hematology, Peter MacCallum Cancer Centre, East Melbourne, Australia;Cabrini Medical Centre, Malvern, Australia
&
Michael DickinsonDepartment of Hematology, Peter MacCallum Cancer Centre, East Melbourne, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, AustraliaCorrespondence[email protected]
Pages 878-880 | Received 08 Sep 2012, Published online: 05 Oct 2012

References

  • Fianchi L, Criscuolo M, Breccia M, . High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma 2012 Aug 30. [Epub ahead of print]
  • Kantarjian H, Issa J-PJ, Rosenfeld CS, . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794–1803.
  • Silverman LR, Demakos EP, Peterson BL, . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429–2440.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
  • Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tumours. Lyon: International Agency for Research on Cancer; 2008:1:76–79.
  • Kenealy M, Giri P, Filshie R, . Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes. Leuk Res 2011;35(Suppl. 1):S22.
  • Cheson BD, Greenberg PL, Bennett JM, . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.
  • Such E, Cervera J, Costa D, . Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011;96:375–383.
  • Beran M, Estey E, O’Brien S, . Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999;17:2819–2830.
  • Wattel E, Guerci A, Hecquet B, . A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. Blood 1996;88:2480–2487.
  • Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87:610–619.
  • Osca-Gelis G, Puig-Vives M, Saez M, . Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993-2007. Leuk Res 2012;36:1262–1266.
  • Costa R, Abdulhaq H, Haq B, . Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011;117:2690–2696.
  • Thorpe M, Montalvão A, Pierdomenico F, Moita F, . Treatment of chronic myelomonocytic leukemia with 5-azacitidine: a case series and literature review. Leuk Res 2012;36:1071–1073.
  • Choi SH, Byun H-M, Kwan JM, . Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol 2007;138:616–623.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.